Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Return on Equity (2020 - 2025)

Ovid Therapeutics' Return on Equity history spans 6 years, with the latest figure at 0.2% for Q4 2025.

  • For Q4 2025, Return on Equity rose 17.0% year-over-year to 0.2%; the TTM value through Dec 2025 reached 0.2%, up 17.0%, while the annual FY2025 figure was 0.18%, 16.0% up from the prior year.
  • Return on Equity reached 0.2% in Q4 2025 per OVID's latest filing, up from 0.72% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.87% in Q1 2021 to a low of 0.72% in Q3 2025.
  • Average Return on Equity over 5 years is 0.23%, with a median of 0.4% recorded in 2022.
  • Peak YoY movement for Return on Equity: surged 216bps in 2021, then crashed -127bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 0.65% in 2021, then crashed by -161bps to 0.39% in 2022, then plummeted by -40bps to 0.55% in 2023, then surged by 34bps to 0.37% in 2024, then surged by 46bps to 0.2% in 2025.
  • Per Business Quant, the three most recent readings for OVID's Return on Equity are 0.2% (Q4 2025), 0.72% (Q3 2025), and 0.66% (Q2 2025).